01—Abstract
Summary
Summary of the 8-K filed February 4, 2026. Cited figures are marked; the original filing is the authoritative source.
Omega Healthcare Investors, Inc. (NYSE: OHI) reported fourth-quarter and full-year 2025 results in a press release furnished as Exhibit 99.1.
For Q4 2025, net income was $172 milliona, or $0.55 per diluted share, versus $116 million, or $0.41 per diluted share, in Q4 2024. Adjusted FFO (AFFO) was $250 million, or $0.80 per diluted share, versus $214 million, or $0.74, and FAD was $238 million, or $0.76 per diluted share, versus $202 million, or $0.70. For full-year 2025, net income was $609 million, or $1.94 per common share, and AFFO was $946 million, or $3.10 per diluted share, compared with $2.87 in 2024.
FAD was $903 millionb, or $2.96 per diluted share, versus $2.73 in 2024, which the CEO described as FAD per share growth of 8.4%. The company completed $1.1 billion of new investments in 2025, including $334 million in Q4, and repaid $1.7 billion of debt. It issued $600 million of 5.2% senior unsecured notes due 2030, entered a new $2.3 billion senior unsecured credit facility, and issued 16 million common shares and 5.5 million Omega OP Units for proceeds or value of $612 million and $222 million.
At December 31, 2025, indebtedness totaled $4.3 billionc at a weighted average interest rate of 4.2%, with $27.0 million of cash and $1.8 billion of undrawn revolver capacity. Management stated leverage reached the lowest level in the company's history. For 2026, Omega guided to Adjusted FFO of $3.15 to $3.25 per diluted share.
The guidance assumes no additional operators are placed on a cash basis, Genesis continues paying its full contractual rent of $13.0 milliond per quarter, and Maplewood pays $6.5 million per month starting in February. The guidance excludes additional acquisitions, capital markets activity, and provisions for credit losses. The Board declared a quarterly dividend of $0.67 per share, payable February 17, 2026.
A conference call is scheduled for February 5, 2026 at 10 a.m. Eastern Time.
02—Key points
Key Highlights
- Q4 2025 AFFO of $250 million, or $0.80 per diluted share, up from $214 million, or $0.74 per diluted share, in Q4 2024.
- Full-year 2025 AFFO of $946 million, or $3.10 per diluted share, compared with $2.87 per diluted share in 2024; FAD of $2.96 per diluted share versus $2.73.
- Completed $1.1 billion of new investments in 2025, including $680 million of real estate acquisitions, $69 million of real estate loans, and $342 million in unconsolidated entities.
- Saber PropCo JV formed in October 2025: Omega acquired a 49% equity interest in a JV owning 64 facilities for approximately 5.5 million OP Units valued at $222 million; the JV now holds 65 facilities generating $70.2 million of contractual rent per annum.
- Balance sheet: $4.3 billion of indebtedness at a 4.2% weighted average interest rate, $27.0 million of cash, and $1.8 billion of undrawn revolver capacity; management cited leverage at the lowest level in company history.
- 2026 AFFO guidance of $3.15 to $3.25 per diluted share; guidance assumes Genesis continues paying $13.0 million per quarter in contractual rent and excludes additional acquisitions and capital markets activity.
- Genesis, which filed for Chapter 11 on July 9, 2025, has made all required contractual rent and interest payments through January 2026; Q4 2025 included $13.0 million of rental income from Genesis.
03—Questions
Frequently Asked Questions
How did Omega perform in the fourth quarter and full year of 2025?
Q4 2025 net income was $172 million ($0.55 per diluted share) and AFFO was $250 million ($0.80 per diluted share), both up from Q4 2024. For full-year 2025, net income was $609 million ($1.94 per common share), AFFO was $946 million ($3.10 per diluted share), and FAD was $903 million ($2.96 per diluted share), compared with $2.73 in 2024.
What is Omega's 2026 earnings guidance?
Omega expects 2026 Adjusted FFO of $3.15 to $3.25 per diluted share. The guidance assumes all new investments disclosed in the press release, no additional operators placed on a cash basis, Genesis paying its full contractual rent of $13.0 million per quarter, and quarterly G&A of approximately $13 million to $15 million. It excludes additional acquisitions, capital markets activity, interest refinancing expenses, and provisions for credit losses.
How did Omega fund its investments and manage its debt in 2025?
Omega issued 16 million common shares and 5.5 million OP Units for proceeds or value of $612 million and $222 million, respectively. It issued $600 million of 5.2% senior unsecured notes due 2030, entered a new $2.3 billion senior unsecured credit facility, and repaid $1.7 billion of debt, including $1.0 billion of senior notes, $479 million of unsecured term loans, and a £183 million GBP secured mortgage loan.
What is the status of Genesis Healthcare, the operator in Chapter 11?
Genesis Healthcare filed for Chapter 11 bankruptcy protection on July 9, 2025. Since filing, Genesis has made all required contractual rent and interest payments through January 2026. Omega recorded $13.0 million of contractual rental income and $4.5 million of interest income from Genesis in Q4 2025, including $4.2 million of paid-in-kind interest.
What dividend did Omega declare and what other recent transactions were disclosed?
On January 29, 2026, the Board declared a quarterly cash dividend of $0.67 per share, payable February 17, 2026 to stockholders of record on February 9, 2026. In January 2026, Omega acquired a 9.9% equity interest in Saber's operating company for $93 million, with minimum quarterly cash distributions equivalent to an annualized yield of 8%. In February 2026, it completed $119 million of real estate acquisitions.
04—Continue